Fulgent: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • Fulgent expects full-year 2026 revenue of $330 million to $340 million.

  • Third-quarter cash reserves reached $652.4 million after a federal tax refund.

  • Laboratory AI slide image analysis volume grew 23% sequentially.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Fulgent (NASDAQ:FLGT) announced full-year 2026 revenue guidance of $330 million to $340 million. Cash reserves reached $652.4 million after the receipt of a federal tax refund, providing financial flexibility as laboratory collections recover. Three things management said stand out.

1. Billing Fixes Are Restoring Laboratory Collection Rates

Management transitioned its revenue cycle management (RCM), billing, and collection software to increase operational efficiency across newly acquired laboratories. Customization delays temporarily depressed collection rates in prior quarters, but operational adjustments delivered immediate sequential margin gains.

While this transition continued to have a negative impact on the third quarter, we are pleased to announce we have made significant progress and have seen a positive sequential trend in reimbursement which has contributed to improvements in our total revenue and gross margins as compared to the second quarter.
-- Brandon Perthuis, Chief Commercial Officer

2. Diagnostic Artificial Intelligence Integration Is Scaling Rapidly

Laboratory automation relies on artificial intelligence (AI, software designed to automate visual pattern recognition) to process tissue samples with high precision. Fulgent has scaled processing volume while reducing software analysis errors, thereby driving diagnostic speed and creating operational efficiency as test volumes grow.

During the third quarter, our AI platform analyzed approximately 255 thousand slide images representing a 23% increase from the second quarter. Importantly, as utilization has scaled, the technical reliability of the platform has improved substantially. With failed analysis declining to just 0.01% during the quarter.
-- Brandon Perthuis, Chief Commercial Officer

3. Targeted Oncology Platform Opens New Therapeutic Opportunities

Beyond diagnostic testing, Fulgent develops nanoencapsulated therapies designed to deliver cancer treatments directly to tumor cells while reducing side effects. Clinical development advanced for candidate FID-007 following a meeting with the Food and Drug Administration (FDA), moving the treatment closer to pivotal Phase 3 trials.

FID-007 is a nano-encapsulated peptide EXO developed under Fulgent's clean chemo platform. The platform is designed to reduce toxicity typically associated with conventional chemotherapy while maintaining or improving efficacy. A profile Fulgent delivery is preferable in combination oncology regimen.
-- Ming Hsieh, Chief Executive Officer

Looking Ahead

Operational momentum is building as billing software fixes take hold and clinical trials advance. Management prioritizes research and development (R&D) investments alongside sales integration, while monitoring reimbursement stability under the Protecting Access to Medicare Act (PAMA), a federal fee schedule framework.

We continue to prioritize our investment across 2 key areas: R&D, where we are advancing both our laboratory testing capabilities and clinical study pipeline and the integration of Bako Diagnostics and StrataDx where we are aligning our expanded sales organization, ... to drive productivity and operating efficiency.
-- Paul Kim, Chief Financial Officer

A cash balance of $652.4 million supports ongoing clinical drug development.

We believe we are well positioned for longer term growth and strategic investments, innovation and expanded offerings that deliver value.
-- Ming Hsieh, Chief Executive Officer

Should you buy stock in Fulgent Genetics right now?

Before you buy stock in Fulgent Genetics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Fulgent Genetics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

The Motley Fool has positions in and recommends Fulgent Genetics. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Market News Today Australia: VIX Jumps Nearly 19%, Gold Hits One-Year Low and Nasdaq 100 FallsNasdaq 100 falls 2.67%, gold hits a one-year low and WTI settles at US$85.72. See what Australian traders are watching ahead of Nvidia earnings.
Author  Mitrade Team
Yesterday 02: 29
Nasdaq 100 falls 2.67%, gold hits a one-year low and WTI settles at US$85.72. See what Australian traders are watching ahead of Nvidia earnings.
placeholder
Stocks, Gold, and Asia Bleed $2.2 Trillion: Top 5 Factors That Triggered the CrashGlobal markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
Author  Beincrypto
Yesterday 02: 49
Global markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
placeholder
Nvidia faces its biggest earnings test yet — why Silicon Valley billionaires want Jensen Huang backNvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
Author  Mark Garro
Yesterday 03: 24
Nvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
placeholder
Gold Price Today: Can XAU/USD Hold $3,870? | Mitrade AUGold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
Author  Mitrade Team
20 hours ago
Gold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
placeholder
Market News Today Australia: Gold Below US$3,900, US Stocks Fall as Nvidia Delivers Strong EarningsUS retail sales rise 0.2%, gold stays below US$3,900 and Nvidia beats earnings estimates. Explore the outlook for Australian CFD traders.
Author  Mitrade Team
2 hours ago
US retail sales rise 0.2%, gold stays below US$3,900 and Nvidia beats earnings estimates. Explore the outlook for Australian CFD traders.
goTop
quote